Table of Contents Table of Contents
Previous Page  762 860 Next Page
Information
Show Menu
Previous Page 762 860 Next Page
Page Background

Table 4 – Randomized controlled trials comparing drug therapy against tamsulosin for nocturia

Study description

Results

Outcome

Comparator

Tamsulosin

Author (yr)

Comparator

Main study

inclusion

criteria

Study

duration

Randomized

patients

Mean

age SD

(range)

Total no.

patients

(

N

)

Mean

difference

(before and after

intervention; SD)

Mean

age SD

(range)

Total no.

patients

(

N

)

Mean

difference

(before and after

intervention; SD)

Mean

difference IV,

fixed, 95% CI

Yee 2015,

[9]

Weight reduction +

a-blocker vs

a-blocker

Men 50,

BPH/LUTS,

BMI 25–35 kg/m

2

12 mo

130

66.5 6.9 (NA)

60

–0.1, 0.3

63.3 7.8 (NA)

57

–0.1, 0.3

0.0

(–0.11, 0.11)

No difference

Simaioforidis

2011,

[24]

Tamsulosin vs

TUR-P

Nocturia for at

least 12 mo and

moderate to

severe LUTS

12 mo

66

69.8 7.9 (53–81)

33

–1, 0.2

67.5 7.1 (52–78)

33

–0.2, 0.2

–0.84

(–0.93, –0.75)

TUR-P appears

superior to

tamsulosin for

BPH related nocturia

Gorgel, 2013,

[46]

Tamsulosin 0.4 mg +

meloxicam 15 mg vs

tamsulosin 0.4 mg

Men 50,

BPH/LUTS,

IPSS:8–19,

Qmax 5–15 ml/s

3 mo

400

61.4 7.5 (NA)

200

–2.7, 0.6

63.3 6.6 (NA)

200

–1.4, 0.4

–1.3

(–1.4, –1.2)

Combination

improves sleep

quality

Oelke 2012,

[39]

Tadalafil 5 mg vs

tamsulosin 0.4 mg

Men 45,

BPH/LUTS, IPSS 13,

Qmax 4–15 ml/s

12 wk

339

63.5 NA (45–83)

171

–0.5, 0.1

63.5 NA (45–84)

167

–0.5, 0.1

0.0 (–0.02, 0.2) No difference

Chapple 2011,

[23]

Silodosin 8 mg vs

tamsulosin 0.4 mg

Men 50, BPH/LUTS,

IPSS 13,

Qmax 4–15 ml/s

12 wk

955

65.8 7.7 (50–87)

371

–0.9, NA

66 7.4 (50–81)

376

–0.8

Not estimable Silodosin is superior

to placebo only

Ukimura 2008,

[21]

N

aftopidil 50 mg vs

tamsulosin 0.2 mg

Men 50 yr, BPH,

OAB, nocturia 2,

flow rate

<

15 ml/s

6–8 wk

59

69.6 6.8 (NA)

25

–3.8, 0.2

68.8 8.2 (NA)

23

–3.1, 0.1

–0.7

(–0.79, –0.61)

Early improvement

(2 wk) in naftopidil

arm but results are

comparable at 8 wk

Ichihara 2014

[26]

Mirabegron +

tamsulosin 0.2 mg vs

tamsulosin 0.2 mg

BPH, OAB

8 wk

96

75.9 7.5 (NA)

38

–0.47, 0.1 73.1 8.7 (NA)

38

–0.16, 0.1 –0.31

(–0.35, –0.27)

The combination is

not superior to

monotherapy

(IPSS Q7)

Ahmed 2015,

[25]

Desmopressin +

tamsulosin vs

tamsulosin 0.4 mg

Men 50 yr, BPH,

LUTS, nocturia 2

3 mo

248

70.1 9.3 (NA)

123

–1.96, 0.2 68.6 10.5 (NA)

125

–1.4, 0.1

–0.55

(–0.58, –0.52)

The combination

improves nocturnal

frequency and first

sleep period

Data modified for the purposes of the table.

BMI = body mass index; BPH = benign prostatic hyperplasia; CI = confidence interval; IPSS = International Prostate Symptom Score; IV = independent variable; LUTS = lower urinary tract symptoms; NA = not available;

NP = nocturnal polyuria; OAB = overactive bladder; SD = standard deviation; TUR-P = transurethral resection of the prostate.

E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 7 5 7 – 7 6 9

762